CureVac’s shareholders approved all proposals relating to BioNTech SE’s public exchange offer for all outstanding shares in CureVac (Offer) at the EGM with an approval rate of over 99.16% of the votes ...

The trial proved so successful that Bayer plans to reach out to regulators in preparation for submitting the drug candidate for approval.

Bayer’s asundexian meets primary efficacy and safety endpoints in landmark phase III OCEANIC-STROKE study in secondary stroke prevention: Berlin Tuesday, November 25, 2025, 11:0 ...

Aanu Adeoye So, Bayer’s drug called asundexian is intended for people who have suffered something called a non-cardioembolic stroke, or people who have suffered a mini stroke, because people who have ...

Bayer issued a "surprisingly positive" report for its blood thinner over the weekend, prodding Bristol Myers Squibb stock ...

Bayer stock jumped on Monday after the German healthcare company said a late-stage stroke drug trial achieved its goals.

Asundexian (Bayer) significantly reduces the risk of ischemic stroke compared with placebo, without increasing the risk of ...

Findings are respite for German conglomerate facing sliding sales of blockbuster drugs and US legal challenges ...

Asundexian is designed to reduce thrombus formation without increasing bleeding risk by selectively inhibiting FXIa.

Asundexian's Phase 3 study results raise hopes for a new class of cardiovascular drugs that has seen clinical setbacks.

Once-daily asundexian 50 mg, on top of antiplatelet therapy, reduced risk for recurrent ischemic stroke after a ...

Novo Nordisk’s weight loss drug semaglutide failed to slow the progression of Alzheimer’s disease in two large trials ...